Month: April 2023

Shoham, Israel, April 07, 2023 (GLOBE NEWSWIRE) — Mobilicom Limited (Mobilicom or the Company, ASX: MOB) advises that in accordance with ASX Listing Rule 3.13.1 it anticipates its Annual General Meeting (“AGM”) will be held on Tuesday 30 May 2023. Accordingly, for the purposes of ASX Listing Rule 3.13.1 and Clause 60(2) of its Constitution, the Company advises that the closing date for nominations for the position of Director is 5:00pm (AEDT) on 18 April 2023. The Company notes that the deadline for nominations for the position of Director is separate to voting on the election of Director. Details of the Directors nominated to be elected will be provided in the Company’s Notice of AGM in due course. -ENDS- Authorised for release by the Board of Mobilicom Limited. About Mobilicom Mobilicom is an end-to-end provider of cybersecurity...

 On 28 April 2023, at 12:00 p.m., an Ordinary General Meeting of Shareholders of AB “Rokiškio sūris” (company code 173057512, registered at the following address: Pramonės g.3, Rokiškis) shall be convened at the head office of AB “Rokiškio sūris” (Pramonės str.3, Rokiškis).  The meeting shall be convened on the initiative of the Company’s Board of Directors in accordance with the decision of the Company’s Board of Directors of 7 April 2023.  Registration starts at 11:00 a.m. and lasts until 11:45 a.m.  Accounting day of the general meeting of shareholders – April 21, 2023.  Record day – May 15, 2023.   Draft Agenda of the General Meeting of Shareholders: Auditor’s findings regarding the consolidated financial reports and annual report. The Audit Committee report. The Company’s consolidated annual report...

On 7 April 2023, the Board of Directors of AB “Rokiškio sūris” approved the audited consolidated and parent company financial statements of the Company for 2022 and the consolidated annual report of the Company for 2022, the draft distribution of the Company’s profit for 2022, and proposed that these statements and the draft distribution of the Company’s profit be submitted to the Ordinary General Shareholders’ Meeting of the Company. The audited consolidated sales of the Rokiškio sūris Group for the year 2022 amount to EUR 359,269 thousand, an increase of 42 per cent compared to the same period of the previous year. Audited consolidated sales for 2021 amounted to EUR 253 062 thousand. The Rokiškio sūris Group generated a net profit of EUR 12 514 thousand in 2022, an increase of EUR 11 961 thousand compared...

ANN ARBOR, Mich., April 07, 2023 (GLOBE NEWSWIRE) — Homepoint, the third-largest wholesale lender by origination volume for the year ending December 31, 2022 according to Inside Mortgage Finance, today announced it has entered into a definitive agreement to sell certain assets of the company’s wholesale originations channel to The Loan Store, Inc., a national wholesale lender headquartered in Tucson, Arizona. “Due to the tremendous effort of our associates and the support of our broker partners, we have built Homepoint from a startup to the third-largest wholesale lender,” said Willie Newman, President and CEO of Homepoint. “After careful consideration, and in light of current market conditions, we have decided to sell our wholesale originations business to The Loan Store. We believe this is the best decision for our company to...

By the initiative and decision of the Vilkyskiu pienine AB (company code 277160980) Board, the Ordinary General Meeting of Shareholders of Vilkyskiu pienine AB is convened at the office of Vilkyskiu pienine AB (P. Lukošaičio str. 14, Vilkyškiai, LT-99254 Pagėgių sav.) on 28 April 2023 at 1 p.m. Shareholders’ registration starts from 12 p.m. until 12.50 p.m. THE AGENDA FOR THE ORDINARY GENERAL MEETING OF SHAREHOLDERS:Approval of Company’s Consolidated annual report for the year 2022. Independent Auditor‘s Report regarding the Company’s consolidated and separated financial Statements for 2022. Approval of Company’s separated and consolidated financial statement for the year 2022.Net Profit (loss) appropriation for the year 2022.Approval of the Remuneration Report of the Company for 2022 which is part of the Annual...

On 7 April 2023 the Board of Vilkyškių pieninė AB (hereinafter Vilkyškių pieninė AB or “the Company”) decided: – To approve the Company’s consolidated annual report for the year 2022, prepared by the Company and assessed by the auditors, and to propose to the Company’s Annual General Meeting of Shareholders to approve Company’s consolidated annual report. – To approve the draft of the audited separated and consolidated financial statements of the Company for the year 2022 and to propose to the Company’s Annual General Meeting of Shareholders to approve it. In 2022, “Vilvi Group“ sales revenue amounted to 234.1 MEUR up by 50 percent from 156 MEUR in 2021. In 2022, the net profit was 12.7 MEUR. – To approve the allocation project of the Company’s audited net profit (loss) under IFRS for the year 2022 (attached) and to...

WHITTIER, Calif., April 07, 2023 (GLOBE NEWSWIRE) — Friendly Hills Bancorp (the “Company”) (OTC Pink: FHLB), the holding company for First Pacific Bank (the “Bank”), today reported the following financial information regarding the Bank’s financial position, including liquidity, capital strength and other information in light of events in the financial industry over the last month. Highlights:The Bank’s total deposits ended the first quarter at $306 million, increasing $40 million or 15% since year end 2022, $17 million of this increase was during the month of March 2023. At March 31, 2023, the Bank had cash and cash equivalents of $19 million, including overnight funds. Unused borrowing capacity from credit facilities in place at March 31, 2023, totaled over $110 million. The Bank’s total assets ended Q1 2023 at $393 million,...

LONDON, April 07, 2023 (GLOBE NEWSWIRE) — WTW (Willis Towers Watson, NASDAQ: WTW), a leading global advisory, broking and solutions company, will announce its financial results for the fourth quarter and full year on Thursday, April 27, 2023 before the market opens. The company will host a conference call to discuss its financial results at 9:00 a.m. Eastern Time on April 27, 2023. A live broadcast of the conference call will be available on WTW’s website here. The conference call will include a question-and-answer session. To participate in the question-and-answer session, please register here. An online replay will be available at www.wtwco.com shortly after the call concludes. About WTW At WTW (NASDAQ: WTW), we provide data-driven, insight-led solutions in the areas of people, risk and capital. Leveraging the global view and...

HAMILTON, Bermuda, April 07, 2023 (GLOBE NEWSWIRE) — Enstar Group Limited (NASDAQ: ESGR) announced today that its wholly-owned subsidiaries have closed a Loss Portfolio Transfer transaction with certain subsidiaries of QBE Insurance Group Limited (“QBE”) on a diversified portfolio of business, covering International and North America financial lines, European and North American reinsurance portfolios, and several US discontinued programs. Enstar’s subsidiaries assumed net loss reserves from QBE of $1.9 billion and will provide approximately $900 million of cover in excess of the ceded reserves on business largely underwritten between 2010 and 2018. The amount of net loss reserves assumed, as well as the settlement and limit amounts provided in the master agreement, will be adjusted for claims paid between January 1, 2023 and the...

IRVINE, Calif., April 07, 2023 (GLOBE NEWSWIRE) — Oncocyte Corporation (Nasdaq: OCX), a precision diagnostic company, today announces the peer-reviewed publication of the results of a study applying DetermaIO™ to samples collected from the randomized Phase II AtezoTRIBE clinical trial in metastatic colorectal cancer (mCRC). The results were published in Clinical Cancer Research and showed the utility of DetermaIO in potentially identifying more responders to ICI therapy than current standard of care biomarkers. Highlights of the peer-reviewed publication include:In the overall population (n=122), DetermaIO positive patients achieved better outcomes in terms of progression-free survival from the addition of atezolizumab among mCRC patients than DetermaIO negative patients, regardless of MMR status. A similar trend was observed...